Baird Financial Group Inc. Sells 27,929 Shares of Amgen, Inc. (AMGN)
Baird Financial Group Inc. reduced its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 8.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 317,419 shares of the medical research company’s stock after selling 27,929 shares during the quarter. Baird Financial Group Inc.’s holdings in Amgen were worth $65,679,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in AMGN. FMR LLC raised its position in Amgen by 4.4% during the third quarter. FMR LLC now owns 35,823,268 shares of the medical research company’s stock valued at $7,425,805,000 after acquiring an additional 1,505,266 shares in the last quarter. Natixis raised its position in Amgen by 2,612.1% during the second quarter. Natixis now owns 529,816 shares of the medical research company’s stock valued at $97,799,000 after acquiring an additional 510,281 shares in the last quarter. Candriam Luxembourg S.C.A. increased its position in shares of Amgen by 54.8% in the third quarter. Candriam Luxembourg S.C.A. now owns 1,075,050 shares of the medical research company’s stock valued at $222,847,000 after buying an additional 380,562 shares in the last quarter. O Shaughnessy Asset Management LLC increased its position in shares of Amgen by 404.6% in the third quarter. O Shaughnessy Asset Management LLC now owns 456,500 shares of the medical research company’s stock valued at $94,333,000 after buying an additional 366,027 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Amgen by 17.0% in the second quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock valued at $436,551,000 after buying an additional 343,690 shares in the last quarter. Institutional investors own 76.94% of the company’s stock.
Shares of NASDAQ:AMGN opened at $197.76 on Thursday. The company has a current ratio of 3.08, a quick ratio of 2.84 and a debt-to-equity ratio of 2.05. The company has a market capitalization of $132.70 billion, a PE ratio of 15.72, a PEG ratio of 2.11 and a beta of 1.41. Amgen, Inc. has a 1 year low of $163.31 and a 1 year high of $210.19.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 7th. Stockholders of record on Friday, November 16th will be paid a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.67%. The ex-dividend date of this dividend is Thursday, November 15th. Amgen’s dividend payout ratio is presently 41.97%.
A number of analysts have recently commented on AMGN shares. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $234.00 price objective for the company in a research report on Monday, October 1st. Mizuho restated a “buy” rating and issued a $206.00 price objective on shares of Amgen in a research report on Friday, October 26th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Amgen in a research report on Thursday, October 25th. Royal Bank of Canada cut their price objective on Amgen to $182.00 and set a “market perform” rating for the company in a research report on Wednesday, October 31st. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $223.00 price objective on shares of Amgen in a research report on Tuesday. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $205.68.
In other news, SVP Cynthia M. Patton sold 1,777 shares of Amgen stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total value of $360,517.76. Following the sale, the senior vice president now directly owns 23,090 shares of the company’s stock, valued at $4,684,499.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.27% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/baird-financial-group-inc-sells-27929-shares-of-amgen-inc-amgn/2663753.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Further Reading: Stock Symbols and CUSIP Explained
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.